Segment reporting (Tables)

9 Months Ended

Apr. 30, 2014

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	14,542			—			—			—		$	14,542
Product revenues		—		$	8,707			—			—			8,707
Royalty and license fee income		—			729			—			—			729
		14,542			9,436			—			—			23,978
Operating expenses:
Cost of clinical laboratory services		9,784			—			—			—			9,784
Cost of product revenues		—			3,800			—			—			3,800
Research and development		—			599		$	250			—			849
Selling, general and administrative		5,091			3,278			—		$	2,236			10,605
Provision for uncollectible accounts receivable		684			—			—			—			684
Legal fee expense		282			766						863			1,911
Legal settlements, net		2,000			(5,100	)		—			—			(3,100	)
Total operating expenses		17,841			3,343			250			3,099			24,533
Operating income (loss)		(3,299	)		6,093			(250	)		(3,099	)		(555	)
Other income (expense)
Interest		(10	)		4			—			(41	)		(47	)
Other		7			(2	)		—			5			10
Foreign currency gain		—			144			—			—			144
Income (loss) before income taxes	$	(3,302	)	$	6,239		$	(250	)	$	(3,135	)	$	(448	)
Depreciation and amortization included above	$	351		$	614		$	—		$	23		$	988
Share-based compensation included in above:
Cost of clinical laboratory services	$	2			1			—			—		$	3
Research and development		—			—			—			—			—
Selling, general and administrative		9		$	(4	)		—		$	275			280
Total	$	11		$	(3	)		—		$	275		$	283
Capital expenditures	$	90		$	36		$	—		$	—		$	126

Three months ended April 30, 2013
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	13,384			—			—			—		$	13,384
Product revenues		—		$	8,265			—			—			8,265
Royalty and license fee income		—			949			—			—			949
		13,384			9,214			—			—			22,598
Operating expenses:
Cost of clinical laboratory services		9,331			—			—			—			9,331
Cost of product revenues		—			4,219			—			—			4,219
Research and development		61			625		$	303			—			989
Selling, general and administrative		5,041			3,813			—		$	2,178			11,032
Provision for uncollectible accounts receivable		887			41			—			—			928
Legal fee expense		115			21			—			1,572			1,708
Total operating expenses		15,435			8,719			303			3,750			28,207
Operating income (loss)		(2,051	)		495			(303	)		(3,750	)		(5,609	)
Other income (expense)
Interest		(12	)		2			—			—			(10	)
Other		6			12			—			7			25
Foreign currency gain		—			(214	)		—			—			(214	)
Income (loss) before income taxes	$	(2,057	)	$	295		$	(303	)	$	(3,743	)	$	(5,808	)
Depreciation and amortization included above	$	354		$	778		$	4		$	25		$	1,161
Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			1			—			—			1
Selling, general and administrative		11		$	—			—		$	126			137
Total	$	13		$	1			—		$	126		$	140
Capital expenditures	$	148		$	18		$	—		$	—		$	166

Nine months ended April 30, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	43,250			—			—			—		$	43,250
Product revenues		—		$	24,424			—			—			24,424
Royalty and license fee income		—			3,366			—			—			3,366
		43,250			27,790			—			—			71,040
Operating expenses:
Cost of clinical laboratory services		28,785			—			—			—			28,785
Cost of product revenues		—			11,511			—			—			11,511
Research and development		14			1,668		$	816			—			2,498
Selling, general and administrative		15,122			10,098			—		$	5,997			31,217
Provision for uncollectible accounts receivable		2,448			20			—			—			2,468
Legal fees expense		572			803			—			3,413			4,788
Legal settlements, net		2,000			(5,100	)								(3,100	)
Total operating expenses		48,941			19,000			816			9,410			78,167
Operating income (loss)		(5,691	)		8,790			(816	)		(9,410	)		(7,127	)
Other income (expense)
Interest		(32	)		13			—			(142	)		(161	)
Other		34			18			—			33			85
Foreign currency gain		—			460			—			—			460
Income (loss) before income taxes	$	(5,689	)	$	9,281		$	(816	)	$	(9,519	)	$	(6,743	)
Depreciation and amortization included above	$	1,061		$	1,876		$	6		$	72		$	3,015
Share-based compensation included in above:
Cost of clinical laboratory services	$	6		$	1			—			—		$	7
Research and development		—			1			—			—			1
Selling, general and administrative		28			5			—		$	456			489
Total	$	34		$	7			—		$	456		$	497
Capital expenditures	$	453		$	117		$	—		$	—		$	570

Nine months ended April 30, 2013
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	41,881			—		—			—		$	41,881
Product revenues		—		$	24,574		—			—			24,574
Royalty and license fee income		—			3,982		—			—			3,982
		41,881			28,556		—			—			70,437
Operating expenses:
Cost of clinical laboratory services		28,466			—		—			—			28,466
Cost of product revenues		—			12,546		—			—			12,546
Research and development		236			1,800	$	932			—			2,968
Selling, general and administrative		14,914			12,165		—		$	6,261			33,340
Provision for uncollectible accounts receivable		3,656			201		—			—			3,857
Legal fee expense		272			58		—			4,520			4,850
Total operating expenses		47,544			26,770		932			10,781			86,027
Operating income (loss)		(5,663	)		1,786		(932	)		(10,781	)		(15,590	)
Other income (expense)
Interest		(34	)		6		—			3			(25	)
Other		31			32		—			18			81
Foreign currency gain		—			119		—			—			119
Income (loss) before income taxes	$	(5,666	)	$	1,943	$	(932	)	$	(10,760	)	$	(15,415	)
Depreciation and amortization included above	$	1,017		$	2,382	$	19		$	79		$	3,497
Share-based compensation included in above:
Cost of clinical laboratory services	$	7			—		—			—		$	7
Research and development		—		$	2		—			—			2
Selling, general and administrative		37			6		—		$	389			432
Total	$	44		$	8		—		$	389		$	441
Capital expenditures	$	579		$	193	$	—		$	—		$	772